Crystalline forms of a biphenyl compound

Abstract

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

1 - 54 . (canceled) 
     
     
         55 . A process for preparing a pharmaceutical composition comprising a solution, the process comprising dissolving a crystalline form of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester in an aqueous carrier to form a solution; wherein the crystalline form is selected from:
 (a) a crystalline diphosphate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 6.4±0.2, 7.6±0.2, 8.6±0.2, 13.7±0.2, 15.0±0.2, 19.4±0.2, 21.6±0.2, 22.1±0.2, 22.9±0.2, and 23.7±0.2;   (b) a crystalline monosulfate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 7.7±0.2, 8.4±0.2, 8.8±0.2, 12.6±0.2, 13.7±0.2, 14.1±0.2, 15.3±0.2, 16.0±0.2, 19.7±0.2, 20.6±0.2, 23.0±0.2, and 24.4±0.2;   (c) a crystalline dioxalate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 7.7±0.2, 8.7±0.2, 13.5±0.2, 14.0±0.2, 14.8±0.2, 15.4±0.2, 15.8±0.2, 19.4±0.2, 22.9±0.2, 23.3±0.2, and 24.6±0.2;   (d) a first crystalline freebase of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 4.7±0.2, 9.6±0.2, 12.7±0.2, 13.7±0.2, 16.7±0.2, 17.4±0.2, 18.5±0.2, 19.4±0.2, 20.8±0.2, 21.4±0.2, 24.2±0.2, and 25.6±0.2; and   (e) a second crystalline freebase of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 4.6±0.2, 9.3±0.2, 12.9±0.2, 13.6±0.2, 14.0±0.2, 14.6±0.2, 16.5±0.2, 18.6±0.2, 19.1±0.2, 20.9±0.2, 22.1±0.2, 22.7±0.2, and 25.7±0.2.   
     
     
         56 . The process of  claim 55 , wherein the pharmaceutical composition is isotonic. 
     
     
         57 . The process of  claim 55 , wherein the pharmaceutical composition has a pH in the range of about 4 to 6. 
     
     
         58 . The process of  claim 55 , wherein the pharmaceutical composition is buffered with citrate buffer to a pH of about 5. 
     
     
         59 . The process of  claim 55 , wherein the pharmaceutical composition contains about 0.05 μg/mL to about 10 mg/mL of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. 
     
     
         60 . The process of  claim 55 , wherein the crystalline form is the crystalline diphosphate salt. 
     
     
         61 . The process of  claim 60 , wherein the crystalline diphosphate salt has powder x-ray diffraction peaks at 2θ values of 15.0±0.2, 19.4±0.2, 21.6±0.2, and 23.7±0.2. 
     
     
         62 . The process of  claim 55 , wherein the crystalline form is the crystalline monosulfate salt. 
     
     
         63 . The process of  claim 62 , wherein the crystalline monosulfate salt has powder x-ray diffraction peaks at 2θ values of 12.6±0.2, 19.7±0.2, 23.0±0.2, and 24.4±0.2. 
     
     
         64 . The process of  claim 55 , wherein the crystalline form is the crystalline dioxalate salt. 
     
     
         65 . The process of  claim 64 , wherein the crystalline dioxalate salt has powder x-ray diffraction peaks at 2θ values of 8.7±0.2, 14.0±0.2, 19.4±0.2, and 22.9±0.2. 
     
     
         66 . The process of  claim 55 , wherein the crystalline form is the first crystalline freebase. 
     
     
         67 . The process of  claim 66 , wherein the first crystalline freebase has powder x-ray diffraction peaks at 2θ values of 4.7±0.2, 18.5±0.2, 20.8±0.2, and 25.6±0.2. 
     
     
         68 . The process of  claim 55 , wherein the crystalline form is the second crystalline freebase. 
     
     
         69 . The process of  claim 68 , wherein the second crystalline freebase has powder x-ray diffraction peaks at 2θ values of 4.6±0.2, 18.6±0.2, 22.1±0.2, and 22.7±0.2. 
     
     
         70 . A pharmaceutical composition comprising a solution of a crystalline form of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester dissolved in an aqueous carrier; wherein the crystalline form is selected from:
 (a) a crystalline diphosphate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 6.4±0.2, 7.6±0.2, 8.6±0.2, 13.7±0.2, 15.0±0.2, 19.4±0.2, 21.6±0.2, 22.1±0.2, 22.9±0.2, and 23.7±0.2;   (b) a crystalline monosulfate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 7.7±0.2, 8.4±0.2, 8.8±0.2, 12.6±0.2, 13.7±0.2, 14.1±0.2, 15.3±0.2, 16.0±0.2, 19.7±0.2, 20.6±0.2, 23.0±0.2, and 24.4±0.2;   (c) a crystalline dioxalate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 7.7±0.2, 8.7±0.2, 13.5±0.2, 14.0±0.2, 14.8±0.2, 15.4±0.2, 15.8±0.2, 19.4±0.2, 22.9±0.2, 23.3±0.2, and 24.6±0.2;   (d) a first crystalline freebase of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 4.7±0.2, 9.6±0.2, 12.7±0.2, 13.7±0.2, 16.7±0.2, 17.4±0.2, 18.5±0.2, 19.4±0.2, 20.8±0.2, 21.4±0.2, 24.2±0.2, and 25.6±0.2; and   (e) a second crystalline freebase of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester characterized by a powder x-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 4.6±0.2, 9.3±0.2, 12.9±0.2, 13.6±0.2, 14.0±0.2, 14.6±0.2, 16.5±0.2, 18.6±0.2, 19.1±0.2, 20.9±0.2, 22.1±0.2, 22.7±0.2, and 25.7±0.2.   
     
     
         71 . The pharmaceutical composition of  claim 70 , wherein the pharmaceutical composition is isotonic. 
     
     
         72 . The pharmaceutical composition of  claim 70 , wherein the pharmaceutical composition has a pH in the range of about 4 to 6. 
     
     
         73 . The pharmaceutical composition of  claim 70 , wherein the pharmaceutical composition is buffered with citrate buffer to a pH of about 5. 
     
     
         74 . The pharmaceutical composition of  claim 70 , wherein the pharmaceutical composition contains about 0.05 μg/mL to about 10 mg/mL of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. 
     
     
         75 . The pharmaceutical composition of  claim 70 , wherein the crystalline form is the crystalline diphosphate salt. 
     
     
         76 . The pharmaceutical composition of  claim 75 , wherein the crystalline diphosphate salt has powder x-ray diffraction peaks at 2θ values of 15.0±0.2, 19.4±0.2, 21.6±0.2, and 23.7±0.2. 
     
     
         77 . The pharmaceutical composition of  claim 70 , wherein the crystalline form is the crystalline monosulfate salt. 
     
     
         78 . The pharmaceutical composition of  claim 77 , wherein the crystalline monosulfate salt has powder x-ray diffraction peaks at 2θ values of 12.6±0.2, 19.7±0.2, 23.0±0.2, and 24.4±0.2. 
     
     
         79 . The pharmaceutical composition of  claim 70 , wherein the crystalline form is the crystalline dioxalate salt. 
     
     
         80 . The pharmaceutical composition of  claim 79 , wherein the crystalline dioxalate salt has powder x-ray diffraction peaks at 2θ values of 8.7±0.2, 14.0±0.2, 19.4±0.2, and 22.9±0.2. 
     
     
         81 . The pharmaceutical composition of  claim 70 , wherein the crystalline form is the first crystalline freebase. 
     
     
         82 . The pharmaceutical composition of  claim 81 , wherein the first crystalline freebase has powder x-ray diffraction peaks at 2θ values of 4.7±0.2, 18.5±0.2, 20.8±0.2, and 25.6±0.2. 
     
     
         83 . The pharmaceutical composition of  claim 70 , wherein the crystalline form is the second crystalline freebase. 
     
     
         84 . The pharmaceutical composition of  claim 83 , wherein the second crystalline freebase has powder x-ray diffraction peaks at 2θ values of 4.6±0.2, 18.6±0.2, 22.1±0.2, and 22.7±0.2.